Severity of the TGN1412 trial disaster cytokine storm correlated with IL‐2 release
Open Access
- 23 May 2013
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 76 (2) , 299-315
Abstract
Aim: To determine if cytokine release with a solid phase assay is predictive of adverse responses for a range of therapeutic mAbs.Methods: Cytokine ELISAs and a multi‐array system were used to compare responses generated by different therapeutic mAbs using a solid phase assay. Flow cytometry was employed to determine the cellular source of those cytokines.Results: Only TGN1412 and muromonab‐CD3 stimulated CD4+ T‐cell mediated cytokine release characterized by significant (all P < 0.0001) IFNγ, TNFα, IL‐2, IL‐4, IL‐5, IL‐10, IL‐12, IL‐13, IL‐17 and IL‐22 release, comparable with T‐cell mitogen. Significantly greater (P < 0.0001) IL‐2 release with TGN1412 (2894–6051 pg ml−1) compared with muromonab‐CD3 (62–262 pg ml−1) differentiated otherwise comparable cytokine responses. Likewise, TGN1412 stimulated significantly more (P = 0.0001) IL‐2 producing CD4+ T‐cells than muromonab‐CD3 and induced Th1, Th2, Th17 and Th22 subsets that co‐release this cytokine. Significant TNFα release was observed with bevacizumab (P = 0.0001), trastuzumab (P = 0.0031) and alemtuzumab (P = 0.0177), but no significant IL‐2 release. TGN1412 and muromonab‐CD3 caused pro‐inflammatory cytokine release despite significantly (both P < 0.0001) increasing numbers of T‐cells with a regulatory phenotype.Conclusions: The severity of the adverse response to TGN1412 compared with muromonab‐CD3 and other therapeutic mAbs correlates with the level of IL‐2 release.Keywords
This publication has 37 references indexed in Scilit:
- Rituximab and Cytokine Release SyndromeCase Reports in Oncology, 2012
- Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapyJournal of Immunological Methods, 2011
- Characterization of Protective Human CD4+CD25+ FOXP3+ Regulatory T Cells Generated with IL-2, TGF-β and Retinoic AcidPLOS ONE, 2010
- Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T‐cellsBritish Journal of Pharmacology, 2010
- Guide to Receptors and Channels (GRAC), 4th editionBritish Journal of Pharmacology, 2009
- Heterogeneity of human effector CD4+ T cellsArthritis Research & Therapy, 2009
- Transient expression of FOXP3 in human activated nonregulatory CD4+ T cellsEuropean Journal of Immunology, 2006
- Human Immunodeficiency Virus Type-1 Infection Impairs the Formation of the Immunological SynapseImmunity, 2006
- Regulation of neutrophil interleukin 8 gene expression and protein secretion by LPS, TNF‐α, and IL‐1βJournal of Cellular Physiology, 1993
- IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATIONTransplantation, 1990